The Effects of Smoking Cessation on Mental Health: Evidence from a Randomized Trial

Katherine Meckel (UCSD Economics) Katherine Rittenhouse (UCSD Economics)

Overview

1 Disclosures

- 2 Introduction and Motivation
- 3 Lung Health Study

4 Data

- 5 Empirical Method
- 6 Results
 - Long-Run EffectsShort-Run Effects

Conclusion

Disclosures

- We have not received any funding for this project
- We have not received any tobacco-related funding in the past
- There are no additional conflicts of interest to disclose

Overview

Disclosures

- 2 Introduction and Motivation
 - 3 Lung Health Study

4 Data

- 5 Empirical Method
- 6 Results
 - Long-Run EffectsShort-Run Effects

Conclusion

Smoking is harmful to the smoker and those around them

- Anti-tobacco policies deter take-up (e.g., taxes) or encourage cessation (e.g., nicotine replacement therapy)
- Should take into account unintended effects on mental health

Mental illness is costly

- ▶ 1 in 5 adults in the U.S. in 2019 (SAMHSA 2020)
- Treatment increases earnings, improves physical health, and increases parental investments in children (Ridley et al. 2020)

Smoking is harmful to the smoker and those around them

- Anti-tobacco policies deter take-up (e.g., taxes) or encourage cessation (e.g., nicotine replacement therapy)
- Should take into account unintended effects on mental health

Mental illness is costly

- ▶ 1 in 5 adults in the U.S. in 2019 (SAMHSA 2020)
- Treatment increases earnings, improves physical health, and increases parental investments in children (Ridley et al. 2020)

- ► Those with mental illness are 2-3x more likely to be smokers
 - Causal mechanisms not well-understood
 - ★ Hypothesis 1: smoking \rightarrow worse mental health
 - ★ Hypothesis 2: poor mental health \rightarrow smoking
 - ★ Hypothesis 3: not causally related, coincide due to SES, genetics, etc.

Effects of nicotine

- Psychoactive drug, acts as stimulant and depressant
 - * may worsen OR relieve anxiety & depression (Picciotto et al, 2002)
- Use of nicotine as "self-medication" (hypothesis 2)
 - * teenagers initiate begin after stressful events (Friedman, 2020);
 - * smokers report smoking improves mood (withdrawal?)

Those with mental illness are 2-3x more likely to be smokers

Causal mechanisms not well-understood

- ★ Hypothesis 1: smoking \rightarrow worse mental health
- ★ Hypothesis 2: poor mental health \rightarrow smoking
- * Hypothesis 3: not causally related, coincide due to SES, genetics, etc.

Effects of nicotine

- Psychoactive drug, acts as stimulant and depressant
 - * may worsen OR relieve anxiety & depression (Picciotto et al, 2002)
- Use of nicotine as "self-medication" (hypothesis 2)
 - * teenagers initiate begin after stressful events (Friedman, 2020);
 - * smokers report smoking improves mood (withdrawal?)

Effects unrelated to nicotine

- Behavioral changes
 - * alcohol as complement (Dee, 1999); social activities
- Depression due to decline in physical health

Thus, smoking and mental health may be related in many ways

- comparisons of mental health b/w smokers and non-smokers are likely biased
- need exogenous variation to estimate causal effects

Effects unrelated to nicotine

- Behavioral changes
 - * alcohol as complement (Dee, 1999); social activities
- Depression due to decline in physical health

Thus, smoking and mental health may be related in many ways

- comparisons of mental health b/w smokers and non-smokers are likely biased
- need exogenous variation to estimate causal effects

Overview

Disclosures

- 2 Introduction and Motivation
- 3 Lung Health Study

4 Data

- 5 Empirical Method
- 6 Results
 - Long-Run EffectsShort-Run Effects

Conclusion

Lung Health Study

- Re-use data from the Lung Health Study (LHS).
 - Randomized controlled trial w/ smokers at risk for COPD
 - Goal: Study effect of prescription inhaler on COPD onset
 - Treatment: intensive cessation intervention + inhaler
 - Followed for the next five years
 - ► Randomization → clean estimation of causal effects
- Study participants included 5,887 at-risk smokers, age 35-65
 - recruited in 1987-1988 at 10 clinical centers in U.S. and Canada
 - no serious illnesses or plans to move away from the clinic area
 - Note, participants more White, college-educated, motivated to quit than average smoker

Lung Health Study

Re-use data from the Lung Health Study (LHS).

- Randomized controlled trial w/ smokers at risk for COPD
- ▶ Goal: Study effect of prescription inhaler on COPD onset
- Treatment: intensive cessation intervention + inhaler
- Followed for the next five years
- Randomization \rightarrow clean estimation of causal effects
- Study participants included 5,887 at-risk smokers, age 35-65
 - recruited in 1987-1988 at 10 clinical centers in U.S. and Canada
 - no serious illnesses or plans to move away from the clinic area
 - Note, participants more White, college-educated, motivated to quit than average smoker

Lung Health Study: Treatment

Three equal groups: two treatment arms, one control arm

- Treated individuals undergo cessation program in early 1989
 - \star One group got prescription inhaler, other gets placebo
- Smoking cessation program:
 - physician's message about lung impairment and disease risk
 - "10 week, 12-session group program emphasizing cognitive and behavioral strategies for cessation"
 - support from family members
 - 6 months of nicotine gum

Lung Health Study: Treatment

▶ Three equal groups: two treatment arms, one control arm

- Treated individuals undergo cessation program in early 1989
 - ★ One group got prescription inhaler, other gets placebo
- Smoking cessation program:
 - O physician's message about lung impairment and disease risk
 - "10 week, 12-session group program emphasizing cognitive and behavioral strategies for cessation"
 - support from family members
 - 6 months of nicotine gum

Lung Health Study

- 5 years of follow-up (1990-1994)
 - Treated individuals return to clinic every 4 months
 - ★ Promote inhaler usage, prevent relapse
 - All individuals re-interviewd annually (5x)
 - * Health and healthcare info, pulmonary testing to validate cessation

Success or failure?

- Cessation program highly effective (sustained quit: 22% vs. 5%)
- Attrition low (96% in year 5)
- BUT inhaler had little added benefit, study deemed "failure" (Anthonisen et al, 1994)
 - $\star \ \rightarrow \text{Many measures left un-examined}$

Lung Health Study

▶ 5 years of follow-up (1990-1994)

Treated individuals return to clinic every 4 months

* Promote inhaler usage, prevent relapse

All individuals re-interviewd annually (5x)

* Health and healthcare info, pulmonary testing to validate cessation

Success or failure?

- Cessation program highly effective (sustained quit: 22% vs. 5%)
- Attrition low (96% in year 5)
- BUT inhaler had little added benefit, study deemed "failure" (Anthonisen et al, 1994)
 - $\star \rightarrow$ Many measures left un-examined

Prior Research using LHS to Estimate Causal Effects

- Increased cessation and lung function after 5 and 11 years (Kanner et al., 1996; Anthonisen et al., 1994; Anthonisen et al., 2002)
- Lower rates of respiratory illness at 5 years (Kanner et al., 2001)
- Reduction in mortality at 14.5 years (Anthonisen et al., 2005)
- ▶ No difference in alcohol usage at 1 year (Murray et al., 1996)
- Increase in BMI of .8 to 1.9 points, or 11-12 lbs for avg male (Courtemanche et al., 2018)
- Spouses also more likely to quit smoking (Fletcher and Marksteiner, 2017)

Overview

Disclosures

- 2 Introduction and Motivation
- 3 Lung Health Study

4 Data

- 5 Empirical Method
- 6 Results
 - Long-Run EffectsShort-Run Effects

Conclusion

Data: Mental Health Outcomes

"Indicate the extent to which you have been troubled in the last four months by any of the following [conditions]: Severe (3), Moderate (2), Mild (1), or Not at all (0)."

- Irritability, insomnia, mood changes, nervousness, psych. illness
- Distress Scale_{it} = sum scores across conditions, for i in year t
- Severe Distress_{it} = share of conditions for which i indicates "severe" in year t

List presc. drugs over last 12 months, bring bottles

- Anti-Depressant_{it} = any anti-depressant taken by i in year t
- Anti-Anxiety_{it} = any anti-anxiety drug taken by *i* in year *t*

Data: Mental Health Outcomes

"Indicate the extent to which you have been troubled in the last four months by any of the following [conditions]: Severe (3), Moderate (2), Mild (1), or Not at all (0)."

- ▶ Irritability, insomnia, mood changes, nervousness, psych. illness
- **Distress Scale**_{*it*} = sum scores across conditions, for *i* in year *t*
- Severe Distress_{it} = share of conditions for which *i* indicates "severe" in year *t*
- List presc. drugs over last 12 months, bring bottles
 - Anti-Depressant_{it} = any anti-depressant taken by i in year t
 - Anti-Anxiety_{it} = any anti-anxiety drug taken by i in year t

Data: Outcomes

Short vs. Long-Run Effects of Quitting

- differentiate b/w effects of nicotine withdrawal and long-term effects
 - * withdrawal may affect 1st interview (+2 months after nic gum runs out)
- ► For each outcome *Y*, define

$$\star Y^{\text{short-run}} = Y_{i1}$$

* $Y^{\text{long-run}} = (1/4) \sum_{2}^{5} Y_{it}$

Data: Outcomes

Short vs. Long-Run Effects of Quitting

- differentiate b/w effects of nicotine withdrawal and long-term effects
 - * withdrawal may affect 1st interview (+2 months after nic gum runs out)
- ► For each outcome *Y*, define

$$\star Y^{\text{short-run}} = Y_{i1}$$

* $Y^{\text{long-run}} = (1/4) \sum_{2}^{5} Y_{it}$

Overview

Disclosures

- 2 Introduction and Motivation
- 3 Lung Health Study

4 Data

- 5 Empirical Method
 - 6 Result
 - Long-Run Effects
 - Short-Run Effects

Conclusion

Empirical Method

• We estimate the causal effect of cessation program as follows:

$$Y_i = \alpha + \beta \text{Treatment}_i + \epsilon_i \tag{1}$$

- ► *Y_i* is a measure of smoking or mental health
- Treatment_i indicates i is assigned to either treatment arm
- ► Adjust *e*_i for heteroskedasticity across individuals
- Alternative approach: IV using cigarettes per day

▶ Random assignment \rightarrow *Treatment*_{*i*} is independent of ϵ_i

- Confirm balanced sample Here
- $\rightarrow \beta$ measures causal effect of cessation intervention on Y_i

Empirical Method

We estimate the causal effect of cessation program as follows:

 $Y_i = \alpha + \beta \text{Treatment}_i + \epsilon_i$

- ▶ *Y_i* is a measure of smoking or mental health
- ▶ *Treatment*_i indicates *i* is assigned to either treatment arm
- Adjust ϵ_i for heteroskedasticity across individuals
- Alternative approach: IV using cigarettes per day

Random assignment \rightarrow *Treatment*_i is independent of ϵ_i

- Confirm balanced sample Here
- $\rightarrow \beta$ measures causal effect of cessation intervention on Y_i

Gender Heterogeneity

- Existing evidence suggests heterogeneous effects by gender
 - Men historically more likely to smoke (Holford et al.2014)
 - Smoking activates male smokers' reward pathways more (Cosgrove et al. 2014), specifically tied to nicotine (Perkins and Karelitz, 2015)

Estimate effects separately for men and women

Gender Heterogeneity

Existing evidence suggests heterogeneous effects by gender

- Men historically more likely to smoke (Holford et al.2014)
- Smoking activates male smokers' reward pathways more (Cosgrove et al. 2014), specifically tied to nicotine (Perkins and Karelitz, 2015)
- Estimate effects separately for men and women

Overview

Disclosures

- 2 Introduction and Motivation
- 3 Lung Health Study
- 4 Data
- 5 Empirical Method
- 6 Results
 - Long-Run Effects
 - Short-Run Effects

Conclusion

Treatment effects on long-run smoking behavior: Here

- ► Sustained quitting ↑ 16.9 pp (307%)
 - ★ men are more responsive than women (337% vs. 262%)
- Treatment works primarily to increase sustained quitting
 - ★ women somewhat more likely to relapse
- ► Cigs/day ↓ 8.1 (38%)
 - ★ treatment also works on intensive margin
 - ★ similar % declines for men and women

14/19

Treatment effects on long-run smoking behavior: Here

► Sustained quitting ↑ 16.9 pp (307%)

★ men are more responsive than women (337% vs. 262%)

Treatment works primarily to increase sustained quitting

★ women somewhat more likely to relapse

- Cigs/day \downarrow 8.1 (38%)
 - treatment also works on intensive margin
 - ★ similar % declines for men and women

14/19

Treatment effects on long-run smoking behavior: Here

▶ Sustained quitting ↑ 16.9 pp (307%)

★ men are more responsive than women (337% vs. 262%)

- Treatment works primarily to increase sustained quitting
 - ★ women somewhat more likely to relapse
- ► Cigs/day ↓ 8.1 (38%)
 - ★ treatment also works on intensive margin
 - ★ similar % declines for men and women

Treatment effects on long-run smoking behavior: Here

- ► Sustained quitting ↑ 16.9 pp (307%)
 - ★ men are more responsive than women (337% vs. 262%)
- Treatment works primarily to increase sustained quitting
 - ★ women somewhat more likely to relapse
- Cigs/day ↓ 8.1 (38%)
 - ★ treatment also works on intensive margin
 - ★ similar % declines for men and women

14/19

Treatment effects on long-run mental health: Here

- Overall, small and insig. effects on distress scale
 - ★ for men, small and insig. increase
 - ★ for women, ↓ 0.25 (10%)
- Effects by components of distress scale: Here and Here
 - $\star\,$ for women, insomnia and nervousness scores $\downarrow\,18\%$ and $13\%\,$
- Severe distress
 - ★ for men, ↑ 0.48, 37% of mean
 - ★ small, negative for women

Treatment effects on long-run mental health: Here

- Overall, small and insig. effects on distress scale
 - ★ for men, small and insig. increase
 - ★ for women, ↓ 0.25 (10%)
- Effects by components of distress scale: Here and Here
 - $\star\,$ for women, insomnia and nervousness scores $\downarrow\,18\%$ and $13\%\,$
- Severe distress
 - ★ for men, ↑ 0.48, 37% of mean
 - ★ small, negative for women

Treatment effects on long-run mental health: Here

- Overall, small and insig. effects on distress scale
 - ★ for men, small and insig. increase
 - ★ for women, ↓ 0.25 (10%)

Effects by components of distress scale: Here and Here

- ★ for women, insomnia and nervousness scores \downarrow 18% and 13%
- Severe distress
 - ★ for men, ↑ 0.48, 37% of mean
 - ★ small, negative for women

Treatment effects on long-run mental health: Here

- Overall, small and insig. effects on distress scale
 - ★ for men, small and insig. increase
 - ★ for women, ↓ 0.25 (10%)
- Effects by components of distress scale: Here and Here
 - $\star\,$ for women, insomnia and nervousness scores $\downarrow\,18\%$ and $13\%\,$

Severe distress

- ★ for men, ↑ 0.48, 37% of mean
- ★ small, negative for women

Treatment effects on long-run mental health: Here

- Likelihood of taking anti-depressants or anti-anxiety drugs
 - * for men, marginally significant increase in anxiolytics of 0.7pp (33%)
 - ★ for women, negative effects, but imprecise
 - * no differences in 2SLS estimates
- To summarize:
 - Women's mental health improved, through reductions in insomnia and nervousness (not Rx)
 - ▶ For men, comparatively worse effects on mental health
 - * no decline overall, but a small increase in severe disturbances

Treatment effects on long-run mental health: Here

- Likelihood of taking anti-depressants or anti-anxiety drugs
 - ★ for men, marginally significant increase in anxiolytics of 0.7pp (33%)
 - ★ for women, negative effects, but imprecise
 - ★ no differences in 2SLS estimates
- To summarize:
 - Women's mental health improved, through reductions in insomnia and nervousness (not Rx)
 - ▶ For men, comparatively worse effects on mental health
 - * no decline overall, but a small increase in severe disturbances

Treatment effects on long-run mental health: Here

- Likelihood of taking anti-depressants or anti-anxiety drugs
 - * for men, marginally significant increase in anxiolytics of 0.7pp (33%)
 - ★ for women, negative effects, but imprecise
 - * no differences in 2SLS estimates

To summarize:

- Women's mental health improved, through reductions in insomnia and nervousness (not Rx)
- ▶ For men, comparatively worse effects on mental health
 - * no decline overall, but a small increase in severe disturbances

Treatment effects on short-run outcomes Here (2SLS estimates: Here)

- Current quit [↑] 26.0 pp (279%)
- Cigs/day↓12.4 (47.9%)
 - ★ Larger than long-term measures
 - ★ Marginally larger effects for men
- ▶ Distress scale ↑ 0.21 (12%)
- - ★ positive for both men and women
 - ★ not statistically different

Treatment effects on short-run outcomes Here (2SLS estimates: Here)

- Current quit ¹/_{26.0} pp (279%)
- ► Cigs/day ↓ 12.4 (47.9%)
 - ★ Larger than long-term measures
 - ★ Marginally larger effects for men
- ▶ Distress scale ↑ 0.21 (12%)
- - ★ positive for both men and women
 - ★ not statistically different

Treatment effects on short-run outcomes Here (2SLS estimates: Here)

- Current quit [↑] 26.0 pp (279%)
- Cigs/day↓12.4 (47.9%)
 - ★ Larger than long-term measures
 - ★ Marginally larger effects for men
- ► Distress scale ↑ 0.21 (12%)
- - ★ positive for both men and women
 - ★ not statistically different

Overview

Disclosures

- 2 Introduction and Motivation
- 3 Lung Health Study

4 Data

- 5 Empirical Method
- 6 Results
 - Long-Run Effects
 - Short-Run Effects

7 Conclusion

Conclusion

Relationship b/w smoking and mental health is not well-understood

- (1) Smoking \rightarrow poor mental health
- (2) Poor mental health \rightarrow smoking
- (3) No causal relationship

Use Lung Health Study to estimate effects of cessation on mental health

- women experience long-run mental health gains (1)
- no evidence of improvements for men (3)

★ in fact, small increase in severe disturbances (2)

Policies that aim to reduce cigarette consumption may have mental health benefits, in particular for women

• Cessation policies and mental health supports may be complementary policies, in particular for men

Conclusion

Relationship b/w smoking and mental health is not well-understood

- (1) Smoking \rightarrow poor mental health
- (2) Poor mental health \rightarrow smoking
- (3) No causal relationship

Use Lung Health Study to estimate effects of cessation on mental health

- women experience long-run mental health gains (1)
- no evidence of improvements for men (3)

★ in fact, small increase in severe disturbances (2)

Policies that aim to reduce cigarette consumption may have mental health benefits, in particular for women

• Cessation policies and mental health supports may be complementary policies, in particular for men

Conclusion

Relationship b/w smoking and mental health is not well-understood

- (1) Smoking \rightarrow poor mental health
- (2) Poor mental health \rightarrow smoking
- (3) No causal relationship

Use Lung Health Study to estimate effects of cessation on mental health

- women experience long-run mental health gains (1)
- no evidence of improvements for men (3)

★ in fact, small increase in severe disturbances (2)

- Policies that aim to reduce cigarette consumption may have mental health benefits, in particular for women
 - Cessation policies and mental health supports may be complementary policies, in particular for men

Contribution

New evidence on causal effects of smoking on mental health

- Inform anti-smoking policy, esp. cessation efforts
 - ★ Under ACA, increased use of cessation aids by low-SES individuals (Cotti et al, 2019)
 - ★ Generate welfare benefits in long-run for women
 - ★ for men, anti-smoking policy and mental health supports may be complementary
 - * Implications for e-cigarettes, which deliver nicotine

Use caution in extrapolating our results

- LHS is more white, urban, & college-educated; only 35-65; at-risk for COPD
- Participants want to quit
- Treatment includes behavioral/cognitive elements (likely short-term)

Contribution

New evidence on causal effects of smoking on mental health

- ▶ Inform anti-smoking policy, esp. cessation efforts
 - * Under ACA, increased use of cessation aids by low-SES individuals (Cotti et al, 2019)
 - * Generate welfare benefits in long-run for women
 - for men, anti-smoking policy and mental health supports may be complementary
 - * Implications for e-cigarettes, which deliver nicotine
- Use caution in extrapolating our results
 - LHS is more white, urban, & college-educated; only 35-65; at-risk for COPD
 - Participants want to quit
 - Treatment includes behavioral/cognitive elements (likely short-term)

	Treatment	Control	Diff	P-Val
Age	48.45	48.48	0.03	0.86
Male	0.62	0.64	0.02	0.21
no HS Diploma	0.12	0.12	-0.00	0.78
HS Diploma	0.30	0.29	-0.01	0.40
Cigs. per Day	31.29	30.99	-0.31	0.39
Age, First Cigarette	17.43	17.57	0.14	0.20
Total Distress Score	1.89	1.81	-0.08	0.25
Distress: Severe	0.02	0.02	-0.00	0.76
Irritability, Past 4 Mos.	0.55	0.52	-0.02	0.28
Insomnia, Past 4 Mos.	0.40	0.39	-0.01	0.74
Mood Changes, Past 4 Mos.	0.40	0.40	-0.01	0.74
Nervous, Past 4 Mos.	0.49	0.46	-0.03	0.14
Psych. Problems, Past 4 Mos.	0.05	0.05	-0.01	0.50
Anti-Depress., Past Year	0.01	0.02	0.00	0.43
Anxiolytic, Past Year	0.03	0.02	-0.00	0.84
Observations	3,812	1,893	5,705	5,705
	1	1 1 1 1		

Pre-Treatment Characteristics, Analysis Sample Back

Sample has non-missing values of long-run distress scale and Rx outcomes.

N 61-	-11	D:		- 2022	
- NIECKI	ei and	Kirren	nouse	. 2022	
				_	e

Smoking Cessation and Mental Health

Long-Run Effects of Cessation Program on Distress Score Components Back



Notes: Displayed above are point estimates and 95% confidence intervals corresponding to β from Eq. (1).

Table: Long-Run Effects of the Cessation Program on Smoking, Part 1 Back

	(1)	(2)	(3)
	Sustained Quit	Current Quit	Cigs per Day
Panel A: All			
Treatment	0.1689	0.1894	-8.0687
	(0.0086)	(0.0101)	(0.3674)
	[0.0000]	[0.0000]	[0.0000]
Obs.	5,627	5,705	5,705
Control Mean	0.0546	0.1724	21.4838

Notes: The dataset is the Lung Health Study, limited to individuals with non-missing values of the dependent variable and the long-run distress score. Each point estimate, heteroskedasticity-robust standard error (in parentheses) and p-value (in brackets) is from a separate regression estimating Eq.
1. At the bottom of the table, we report p-values from a Chi-squared test of whether the difference in coefficients for men and women is equal to 0.

	(1)	(2)	(3)
	Sustained Quit	Current Quit	Cigs per Day
Panel B: Men			
Treatment	0.1843	0.1922	-8.6535
	(0.0110)	(0.0129)	(0.4880)
	[0.0000]	[0.0000]	[0.0000]
Obs.	3,519	3,575	3,575
Control Mean	0.0546	0.1779	22.4267
Panel C: Women			
Treatment	0.1438	0.1854	-6.9925
	(0.0137)	(0.0163)	(0.5374)
	[0.0000]	[0.0000]	[0.0000]
Obs.	2,108	2,130	2,130
Control Mean	0.0547	0.1627	19.8210
P-Value, Men-Women	0.0214	0.7420	0.0221
Meckel and Rittenhouse, 2022	Smoking Cessation and Men	tal Health Aug	1st 11, 2022 4 / 19

Table: Long-Run Effects of the Cessation Program on Smoking, Part 2 Back

	(1)	(2)	(3)	(4)
	Distress Scale	Distress: Severe	Anxiolytic	Anti-Depressant
Panel A: All				
Treatment	-0.0436	0.0016	0.0082	-0.0024
	(0.0671)	(0.0020)	(0.0072)	(0.0074)
	[0.5165]	[0.4187]	[0.2563]	[0.7514]
Obs.	5,705	5,705	5,705	5,705
Control Mean	1.7719	0.0204	0.0681	0.0766

Table: Long-Run Effects of Cessation Program on Mental Health, Part 1 Back

Notes: Each point estimate, heteroskedasticity-robust standard error (in parentheses) and p-value (in brackets) is from a separate regression estimating Eq. 1. We estimate IV regressions of the effects of smoking cigarettes on these outcomes (Eq. 3) separately for men and women. At the bottom of the table, we report the difference between these estimates and the p-value from a Chi-squared test of whether the difference in coefficients is equal to 0.

	(1)	(2)	(3)	(4)
	Distress Scale	Dist: Severe	Anxiolytic	Anti-Dep.
Panel B: Men				
Treatment	0.0558	0.0048	0.0068	-0.0026
	(0.0762)	(0.0022)	(0.0039)	(0.0044)
	[0.4644]	[0.0259]	[0.0824]	[0.5557]
Obs.	3,575	3,575	3,575	3,575
Control Mean	1.4151	0.0131	0.0206	0.0266
Panel C: Women				
Treatment	-0.2510	-0.0046	-0.0020	-0.0055
	(0.1231)	(0.0038)	(0.0071)	(0.0076)
	[0.0416]	[0.2307]	[0.7747]	[0.4714]
Obs.	2,130	2,130	2,130	2,130
Control Mean	2.4010	0.0334	0.0448	0.0523
Diff, M-W: b/cigs	-0.0423	-0.0012	-0.0011	-0.0005
P-Value	0.0309	0.0438	0.3326	0.6897
Meckel and Rittenhouse, 202	22 Smoking Cessa	tion and Mental Health	August 11, 2	2022 6 / 19

Table: Long-Run Effects of Cessation Program on Mental Health, Part 2 Back

	(1)	(2)	(3)	(4)	(5)	(6)
	Quit	Cigs/Day	Distress Scale	Dist.: Severe	Anxiolytic	Anti-Dep.
Panel A: All						
Treatment	0.2604	-12.3920	0.2113	0.0051	0.0010	0.0035
	(0.0102)	(0.3649)	(0.0704)	(0.0025)	(0.0044)	(0.0038)
	[0.0000]	[0.0000]	[0.0027]	[0.0388]	[0.8272]	[0.3585]
Obs.	5,705	5,484	5,474	5,497	5,497	5,497
Control Mean	0.0930	25.9182	1.6778	0.0181	0.0241	0.0164

Notes: Each point estimate, heteroskedasticity-robust standard error (in parentheses) and p-value (in brackets) is from a separate regression estimating Eq. 1. At the bottom of Columns (2) and (3), we report the p-value from a Chi-squared test of whether the coefficient estimates for men and women are equal. At the bottom of Columns (3)-(5), we report the difference between these estimates and the p-value from a test of whether they are equal.

		(-)	(-)		(-)	
	(1)	(2)	(3)	(4)	(5)	(6)
	Quit	Cigs/Day	Distress Scale	Dist.: Severe	Anxiolytic	Anti-Dep.
Panel B: Men						
Treatment	0.2735	-13.7460	0.2286	0.0056	0.0013	0.0025
	(0.0129)	(0.4766)	(0.0813)	(0.0026)	(0.0050)	(0.0039)
	0.0000	0.0000	[0.0050]	[0.0334]	[0.7942]	[0.5338]
Obs.	3,575	3,418	3,410	3,427	3,427	3,427
Control Mean	0.0911	27.4547	1.3804	0.0117	0.0190	0.0112
Panel C: Women						
Treatment	0.2386	-10.0173	0.1470	0.0036	-0.0002	0.0044
	(0.0168)	(0.5450)	(0.1272)	(0.0049)	(0.0084)	(0.0076)
	[0.0000]	[0.0000]	[0.2482]	[0.4700]	[0.9813]	[0.5592]
Obs.	2,130	2,066	2,064	2,070	2,070	2,070
Control Mean	0.0964	23.2489	2.1940	0.0291	0.0330	0.0255
Diff, M-W: b/cigs			-0.0033	0.0000	-0.0001	0.0003
P-Value	0.0987	0.0000	0.7927	0.9376	0.9026	0.7383

Table: Short-Run Effects of Cessation Program, Part 2 Back

Meckel and Rittenhouse, 2022

Smoking Cessation and Mental Healt

August 11, 2022 8 / 19

	(1)	(2)	(3)	(4)
	Distress Scale	Distress: Severe	Anxiolytic	Anti-Dep.
Panel A: Men				
Avg. Cigarettes per Day, Years 2-5	-0.0064	-0.0006	-0.0008	0.0003
	(0.0089)	(0.0003)	(0.0005)	(0.0005)
	[0.4666]	[0.0285]	[0.0836]	[0.5560]
Obs.	3 <i>,</i> 575	3 <i>,</i> 575	3,575	3,575
Control Mean, Men	1.4151	0.0131	0.0206	0.0266
F-Statistic	315	315	315	315
Panel B: Women				
Avg. Cigarettes per Day, Years 2-5	0.0359	0.0007	0.0003	0.0008
	(0.0175)	(0.0005)	(0.0010)	(0.0011)
	[0.0403]	[0.2284]	[0.7749]	[0.4726]
Obs.	2,130	2,130	2,130	2,130
Control Mean, Women	2.4010	0.0334	0.0448	0.0523
F-Statistic	169	169	169	169
Meckel and Rittenhouse, 2022 Smol	king Cessation and Me	ntal Health	August 11, 2022	9 / 19

Table: Long-Run Effects on Mental Health, 2SLS Estimates Back

	(1)	(2)	(3)	(4)	(5)
	Irritation	Insomnia	Moodiness	Nervous	Psych. Illness
Panel A: All					
Treatment	-0.0084	-0.0300	-0.0058	-0.0057	0.0068
	(0.0195)	(0.0212)	(0.0175)	(0.0193)	(0.0092)
	[0.6674]	[0.1578]	[0.7398]	[0.7699]	[0.4598]
Obs.	5,705	5,705	5,705	5,705	5,705
Control Mean	0.4697	0.4526	0.3589	0.4057	0.0850

Each point estimate, heteroskedasticity-robust standard error (in parentheses) and p-value (in brackets) is from a separate 2SLS regression estimating Eq. 3. At the bottom of the table, we report the F-Statistic from the first stage regression (Eq. 2).

	(1)	(2)	(3)	(4)	(5)
	Irritation	Insomnia	Moodiness	Nervous	Psych. Illness
Panel B: Men					
Treatment	0.0078	0.0157	-0.0076	0.0287	0.0112
	(0.0226)	(0.0237)	(0.0205)	(0.0212)	(0.0104)
	[0.7303]	[0.5086]	[0.7104]	[0.1744]	[0.2835]
Obs.	3,575	3,575	3,575	3,575	3,575
Control Mean	0.3960	0.3411	0.3096	0.3037	0.0648
Panel C: Women					
Treatment	-0.0440	-0.1188	-0.0091	-0.0748	-0.0029
	(0.0354)	(0.0399)	(0.0317)	(0.0369)	(0.0174)
	[0.2137]	[0.0030]	[0.7747]	[0.0427]	[0.8674]
Obs.	2,130	2,130	2,130	2,130	2,130
Control Mean	0.5998	0.6494	0.4457	0.5856	0.1204
Diff, M-W: b/cigs	-0.0072	-0.0188	-0.0004	-0.0140	-0.0017
P-Value	0.2057	0.0030	0.9348	0.0153	0.5363
Meckel and Rittenhouse. 2	2022 Sm	oking Cessation an	d Mental Health	August	11,2022 11/19

Table: Long-Run Effects on Distress Score Components, Part 2 Back

	(1)	(2)	(3)	(4)
	Distress Scale	Distress: Severe	Anxiolytic	Anti-Dep.
Panel A: Men				
Avg. Cigarettes per Day, Year 1	-0.0161 (0.0058) [0.0054]	-0.0004 (0.0002) [0.0388]	-0.0001 (0.0003) [0.7941]	-0.0002 (0.0003) [0.5351]
Obs. Control Mean, Men F-Statistic	3,575 1.3804 71	3,575 0.0117 71	3,575 0.0190 71	3,575 0.0112 71
Panel B: Women				
Avg. Cigarettes per Day, Year 1	-0.0128 (0.0112) [0.2514]	-0.0003 (0.0005) [0.4736]	0.0000 (0.0008) [0.9813]	-0.0004 (0.0007) [0.5608]
Obs. Control Mean, Women F-Statistic	2,130 2.1940 27	2,130 0.0291 27	2,130 0.0330 27	2,130 0.0255 27
Markal and Pittanhouse 2022	making Cossotion and	Montal Haslth	August 11, 2022	12 / 19

Table: Short-Run Effects on Mental Health, 2SLS Estimates Back

Dynamic Effects of Cessation Program on Distress Scale



Meckel and Rittenhouse, 2022

Smoking Cessation and Mental Health

Dynamic Effects of Cessation Program on Severe Distress



Meckel and Rittenhouse, 2022

Smoking Cessation and Mental Health

Dynamic Effects of Cessation Program on Anxiolytic Usage



Meckel and Rittenhouse, 2022

Smoking Cessation and Mental Health

Dynamic Effects of Cessation Program on Anti-Depressant Usage



Meckel and Rittenhouse, 2022

Smoking Cessation and Mental Health

]	(1) Distress Scale	(2) Distress: Severe	(3) Anxiolytic	(4) Anti-Depressant
Treatment \times Year 1	0.2188	0.0054	0.0005	0.0035
	(0.0697)	(0.0025)	(0.0044)	(0.0037)
	[0.0017]	[0.0283]	[0.9083]	[0.3561]
Treatment \times Year 2	0.0075	0.0037	0.0034	0.0028
	(0.0657)	(0.0023)	(0.0047)	(0.0048)
	[0.9089]	[0.1030]	[0.4772]	[0.5569]
Treatment \times Year 3	-0.0354	0.0011	0.0042	-0.0024
	(0.0617)	(0.0020)	(0.0049)	(0.0050)
	[0.5665]	[0.5911]	[0.3890]	[0.6271]
Treatment $ imes$ Year 4	-0.0796	0.0006	0.0054	-0.0065
	(0.0620)	(0.0020)	(0.0049)	(0.0052)
	[0.1995]	[0.7580]	[0.2617]	[0.2138]
Treatment × Year 5	-0.0083	-0.0009	0.0080	-0.0064
	(0.0631)	(0.0023)	(0.0051)	(0.0058)
	[0.8955]	[0.6928]	[0.1146]	[0.2742]
Obs.	27,447	27,555	27,555	27,555
Control Mean	1.3819	0.0155	0.0274	0.0315
Meckel and Rittenhouse, 202	2 Smokir	ng Cessation and Mental Health	Augus	st 11, 2022 17 / 19

Table: Dynamic Effects of Cessation Program on Mental Health, Pooled Sample

	(1) Distress Scale	(2) Distress: Severe	(3) Anxiolytic	(4) Anti-Depressant	
Treatment \times Year 1	0.2423	0.0062	0.0004	0.0020	
	(0.0805)	(0.0026)	(0.0049)	(0.0040)	
	[0.0026]	[0.0174]	[0.9285]	[0.6148]	
Treatment \times Year 2	0.0063	0.0040	0.0063	-0.0006	
	(0.0760)	(0.0026)	(0.0050)	(0.0050)	
	[0.9344]	[0.1206]	[0.2072]	[0.9051]	
Treatment $ imes$ Year 3	0.0553	0.0035	0.0093	-0.0021	
	(0.0686)	(0.0019)	(0.0051)	(0.0052)	
	[0.4199]	[0.0617]	[0.0680]	[0.6881]	
Treatment $ imes$ Year 4	0.0475	0.0042	0.0076	-0.0027	
	(0.0695)	(0.0021)	(0.0055)	(0.0056)	
	[0.4944]	[0.0517]	[0.1643]	[0.6314]	
Treatment $ imes$ Year 5	0.0599	0.0022	0.0108	-0.0041	
	(0.0720)	(0.0025)	(0.0056)	(0.0065)	
	[0.4049]	[0.3713]	[0.0527]	[0.5329]	
	15 100	17 100	1= 100	1= 100	
Obs.	17,132	17,199	17,199	17,199	
Meckel and Rittenhouse, 20.	22 Smoking	Cessation and Mental Health	Augu	August 11, 2022 18 / 19	

Table: Dynamic Effects of Cessation Program on Mental Health, Men

I	(1) Distress Scale	(2) Distress: Severe	(3) Anxiolytic	(4) Anti-Depressant
Treatment $ imes$ Year 1	0.1462	0.0033	0.0001	0.0053
	(0.1261)	(0.0049)	(0.0083)	(0.0075)
	[0.2463]	[0.4975]	[0.9916]	[0.4794]
Treatment $ imes$ Year 2	-0.0237	0.0027	-0.0028	0.0072
	(0.1188)	(0.0044)	(0.0095)	(0.0096)
	[0.8416]	[0.5393]	[0.7696]	[0.4524]
Treatment $ imes$ Year 3	-0.2271	-0.0037	-0.0058	-0.0044
	(0.1166)	(0.0043)	(0.0098)	(0.0100)
	[0.0516]	[0.3787]	[0.5589]	[0.6599]
Treatment $ imes$ Year 4	-0.3135	-0.0057	0.0013	-0.0139
	(0.1155)	(0.0040)	(0.0092)	(0.0104)
	[0.0067]	[0.1528]	[0.8877]	[0.1845]
Treatment × Year 5	-0.1532	-0.0068	0.0023	-0.0114
	(0.1170)	(0.0047)	(0.0100)	(0.0111)
	[0.1907]	[0.1447]	[0.8186]	[0.3054]
Obs.	10,315	10,356	10,356	10,356
Control Mean	1.8622	0.0256	0.0417	0.0468
Meckel and Rittenhouse, 2022	Smoki	ng Cessation and Mental Health	Augu	st 11, 2022 19 / 19

Table: Dynamic Effects of Cessation Program on Mental Health, Women